Abstract: Diseases of the cerebral venous system frequently lead to neuro-ophthalmic complications. Cortical venous sinus thrombosis and dural arteriovenous fistulas may be complicated by elevation of intracranial pressure, with secondary papilledema or abducens palsies. There is increasing recognition that stenosis at the transverse sinussigmoid sinus junction plays a role in the pathophysiology of idiopathic intracranial hypertension and offers a new avenue of treatment in patients who fail medical therapy. Diseases of the cavernous sinus manifest with their own set of neuro-ophthalmic symptoms, reflecting the presence of all 3 ocular motor nerves and the oculosympathetic fibers within its walls, along with its role as the primary drainage pool of the globe and orbit. Numerous questions and controversies remain regarding the diagnosis and optimal treatment of cerebral venous disease, including the role of venous stenting in idiopathic intracranial hypertension, the role of anticoagulation in cavernous sinus thrombosis, and the risks and benefits of embolization of mild indirect cavernous carotid fistulas.
VENOUS SINUS STENOSIS AND IDIOPATHIC INTRACRANIAL HYPERTENSION Statement 1: Venous Sinus Stenosis Plays a Role in IIH.

For
The notion that venous hemodynamics plays a role in IIH is nothing new. In Quincke's first description of the disease in 1893, 1 he pointed out that, "In general, venous stasis (as in valvular heart disease) we see, in addition to edema of the brain substance, increase in fluid not only in the ventricles, but also, and usually in a higher degree, in the subarachnoid space… ." Forty-four years later, Walter Dandy 2 hypothesized in his seminal paper on IIH that "variations in the intracranial vascular bed" might contribute to the observed elevation of ICP. Indeed, as high ICP and papilledema mimicking IIH can be seen in the setting of VST, 3 occlusion of cerebral sinuses by tumor, or iatrogenic takedown of the internal jugular veins, it is logical to assume that aberrations in venous drainage might play a role in classic IIH as well.
The study of King et al 4 revealed an elevation in venous sinus pressure in the superior sagittal sinus and proximal transverse sinuses of 7 patients with IIH, with a mean pressure gradient along the transverse sinus of 13.3 mm Hg, versus a mean of 1.4 mm Hg only in controls; these suggest that stenosis can affect venous flow, producing the syndrome of IIH. As there was no observed gradient in 2 cases of minocycline-induced IIH, one can surmise that such a trans-stenotic gradient is only etiological in truly idiopathic cases and not required when drug-induced perturbations in CSF production or absorption are produced, for example. Later in 2003, using an auto-triggered elliptic centric-ordered 3-dimensional gadolinium-enhanced magnetic resonance venography (ATECO MRV) technique, Farb et al 5 showed venous sinus stenosis (VSS) at the transverse-sigmoid sinus junction in 27/29 (93%) of IIH cases and only 4/59 (7%) of controls, and demonstrated that stenosis was relatively rare outside of IIH, suggesting its recognition should prompt one to rule out IIH. In fact, they found that a combined conduit score, a grading scale to assess transverse-sigmoid sinus stenosis in patients with IIH, is reflective of the degree of stenosis-predicted IIH with a high degree of sensitivity and specificity (both 93%). Kelly et al 6 found that only 7/240 (3%) adults sent for MRV for reasons other than IIH had VSS, confirming that asymptomatic VSS was rare. Because 6/7 of these patients had an empty sella, 2 had prominence of perineural sheaths, and 1 flattening of the posterior sclera, it is possible that these patients had a subclinical form of IIH that was sufficient to cause radiological changes; this notion is supported by the high-normal opening pressures (22) (23) (24) (25) cm H 2 O) found in the 5 patients who underwent lumbar puncture (LP) .
Although the association between VSS and IIH does not prove causation, the resolution of symptoms and signs of IIH with stenting observed in multiple studies implies an important role for VSS in the disease, as otherwise its eradication will not likely produce a clinical improvement. While a correlation between the degree of VSS and severity of IIH has not been demonstrated (see below), such a correlation is not necessary for a factor to be causative of a disease. Instead, a critical point could be reached (in this case, a certain cut-off degree of stenosis) after which the disease resulted, without any worsening with further progression beyond that critical point. Furthermore, CSF pressure is related to multiple factors and can be modeled by the following equation: ICP = R out × Formation Rate csf + Pressure SSS where R out is the outflow resistance of the arachnoid granulations, Formation Rate csf is the rate of CSF production, and Pressure SSS is the pressure in the superior sagittal sinus
As only Pressure SSS would be directly related to VSS, any given patient might have a different threshold for the acceptable degree of stenosis, depending on the resistance at the granulations and the formation rate of CSF.
Against
Findings of VSS in the majority of IIH cases need to be interpreted with caution. Association does not prove causation, and as will be discussed below, in many cases, VSS may in fact result from elevated ICP, suggesting that it is an innocent bystander of the disease and not its cause. If VSS is a primary cause of IIH, one may expect some correlation of the degree of stenosis with the severity of the disease. Yet, Riggeal et al 7 demonstrated in 2013 that in 51 patients with IIH and VSS, no correlation was found between the percent stenosis and a good clinical outcome, the visual field grade, or the CSF opening pressure. In our own cohort, 8 we also found no correlation between the degree or length of stenosis and the CSF opening pressure. Furthermore, non-contrast MRV measurements can be confounded by the interaction of venous flow dynamics and the plane of projection. It is, therefore, important to use contrastenhanced MRV to screen for stenosis, and ultimately direct measurement of the trans-stenotic gradient using conventional venography is required to confirm that a region of stenosis is hemodynamically significant. Finally, a careful analysis of the obstruction flow pattern on MRV should be performed before proceeding to conventional venography. Unilateral stenosis, for example, is not considered to be hemodynamically significant unless the contralateral transverse sinus is hypoplastic. Thus, consideration of stenting should only be made in cases where there is either bilateral stenosis or unilateral stenosis in the setting of contralateral hypoplasia.
The observation of improvement in IIH symptoms and signs after venous sinus stenting needs to be interpreted with caution, as most stenting studies are retrospective and are neither blinded nor controlled. In terms of elucidating the underlying mechanism of IIH, even if stenting a narrowed venous segment allows a reduction in ICP that is effective in patients with IIH, this does not prove that the stenosis plays an important role in IIH. By analogy, although a reduction in CSF production using acetazolamide with weight loss is superior to weight loss alone for mild IIH (as shown by the Idiopathic Intracranial Hypertension Treatment Trial 9 ), this does not necessarily mean that overproduction of CSF plays an important role in IIH. 12 showed immediate resolution of VSS in a patient using intravascular ultrasonography performed immediately before and after a high-volume LP. Indeed, we have observed the same reversibility of VSS in some patients after LP or CSF diversion procedure and recurrence of the stenosis after shunt failure (Fig. 1 ).
Although VSS may sometimes reverse with reduction in CSF pressure, in many cases, the stenosis is unaffected by a reduction in ICP. Bono et al, 13 for example, presented 9 patients of whom VSS persisted after normalization of ICP. Thus, it has become clear that some patients with IIH may have 'extrinsic' stenosis, which is typically tapered and gradual, primarily the result of compression of a vulnerable segment of venous sinus by elevated ICP, whereas others have a more focal, anatomical stenosis, 14 resulting from swollen arachnoid granulations, septal bands, or presumed organized chronic thrombosis. Some of the intrinsic cases seem to be congenital. In fact, Connor et al 15 have demonstrated either a narrowing or absence of the bony groove within which the transverse sinus courses in 5/23 (narrowing) and 8/23 (absence) patients with IIH. Associated bony changes support the argument that, at least in those particular cases, the stenosis was not acquired. 
For
The resolution of extrinsic stenosis with reduction in ICP reveals that it could not be the sole contributor to the pathophysiology of IIH. Instead, it is more likely that it is one of several hits that together create a perfect storm producing IIH. In fact, although transverse sinus stenting seems to be quite successful in reducing ICP, producing a significant reduction in ICP in all but 2 of 45 patients in our cohort, in many of these patients, the final ICP is still 24 cm H 2 O or higher, suggesting that other factors cause an initial elevation in ICP and are not reversed by the eradication of VSS. The self-limiting venous collapse feedback loop model compares the venous tree sitting within the cranium and exposed to ICP as a Starling resistor. In this model, the fluidity of the venous blood (how easily it flows) depends on the absence or presence of stenosis, which in turn depends on the difference between the ICP and internal venous pressure (assuming a collapsible segment of vein). Thus, the venous flow will be decreased by elevations in CSF pressure. However, the model also assumes that the CSF pressure is, in turn, dependent on venous flow. One can imagine an initial elevation in CSF (due to weight gain or hormonal changes presumably, given the demographic features of IIH), which reaches a critical point to cause VSS. The VSS eventually is high enough to worsen ICP and a positive feedback loop ensues. Thus, although stenting extrinsic stenosis might not normalize ICP completely, it could theoretically reverse the bulk of abnormal elevation (all that was produced by this positive feedback loop), the driving gears of which have now been removed. This idea was demonstrated by Buell et al, 12 who found the patient had a recrudescence of symptoms and recurrence of both ICP elevation and the VSS 1 month after observing a complete resolution of the VSS with LP. Stenting of this stenosis, which was clearly extrinsic, led to a complete resolution of the ICP symptoms.
Against
The resolution of extrinsic stenosis with reduction in ICP demonstrates not only that association does not prove causation, but also that in some cases, the vector of causation may point in the opposite direction. One might consider heeding advice from Rohr et al, 11 therefore, to avoid stenting patients with extrinsic stenosis.
Discussion of statements 4 to 6 is based upon our review of 25 studies and 10 case reports in the literature, totaling 538 patients, extending our prior meta-analysis of the literature. 
For
Although only a minority of stent patients underwent prestent and poststent LPs, the available data from these patients suggest that stenting does lead to a reduction in ICP. In 79/92 patients, there was an improvement in opening pressure, with a mean reduction from 35 
Against
Evidence for a reduction of ICP after venous stenting in IIH needs to be tempered by the fact that the majority of studies did not test both prestent and poststent opening pressures. Of 25 studies to date, only 17 included prestent data in the majority of patients, yielding prestent opening pressures in 256/538 subjects. On the other hand, 7 studies, with a total of 92 patients, included poststent data; thus, less than 20% of patients in the literature have prestent and poststent data for comparison. 16 Furthermore, the timing of poststent LPs was not uniform, and it is difficult to find out whether improvements in ICP are in fact due to concomitant weight loss or ongoing treatment with acetazolamide. One of the challenges in acquiring poststent opening pressure data is the fact that these patients are on dual antiplatelet therapy for the first month after the procedure. We therefore waited until at least the 6-week point to perform poststent LP, when the patient is on aspirin monotherapy and the procedure can be performed with greater safety.
Statement 5: There is Evidence That Venous Stenting Prevents or Reverses Vision Loss in Patients with Medically Refractory IIH.
For
Although it is true that the bulk of stent studies did not analyze visual acuity and visual fields quantitatively, data from several studies buttress the claim that stenting can help restore visual function in patients with IIH, along with visual symptom data from the bulk of studies that are supportive. Updating our prior review of the literature, 16 we found that of 221 patients with visual complaints undergoing stenting for IIH, 145 (66%) were reported to experience significant improvement in those symptoms and 68/102 (67%) with transient visual obscurations reported its resolution. Of 204 eyes with a drop in visual acuity, 112 (55%) experienced an improvement after venous stenting, whereas 92 (45%) did not. Of 206 eyes with reported visual field loss, 135 (66%) improved, 45 (22%) experienced no change, and 11 (5%) worsened. These numbers hold up against the improvement in vision in 59% of patients undergoing optic nerve sheath fenestration (ONSF) and 54% of patients receiving CSF diversion procedure reported by Satti et al 23 in their meta-analysis covering studies from 1988 to 2014. Furthermore, 135/206 eyes with documented visual field loss experienced improvement in visual fields over time. Looking at the data from the 3 studies that compared mean deviation prestenting and poststenting, an improvement in mean deviation by 3.29 dB (from −10.35 to −7.05 dB) has been observed. 8, 14, 24 In our own study, 25 looking at 48 eyes (only in patients where at least 1 eye had papilledema at presentation) before stenting and approximately 3 months after stenting, mean deviation improved from −10.1 to −4.67 dB, with an improvement demonstrated in 44/48 eyes.
Against
The visual assessment in patients undergoing stenting for IIH in the literature is haphazard and difficult to interpret. Of 25 studies, 16 only 7 (yielding 160 eyes) included specific data on visual acuity prestenting and poststenting; these increase to 177 eyes with inclusion of case reports. In one of the studies, only the mean visual acuity in the right and left eyes was reported, making a comprehensive assessment even more difficult. The overall visual acuity improved a small amount, from logarithm of the minimum angle of resolution 0.25 (Snellen 20/36) to 0.136 (20/27) , indicating that papilledema does not typically cause a significant drop in visual acuity; this implies that visual fields must be assessed if one is to truly measure the effect of any intervention on vision. Three studies reported qualitative assessment of formal visual fields 14, 17, 26 and only 3 8, 19, 24 performed a quantitative analysis of visual fields including mean deviations prestenting and poststenting. Thus, our true understanding of the effect of stenting on visual fields is based on 71 eyes only. 
For
Adverse effects and complications may occur with venous stenting but their rate and severity are comparable to other surgical procedures for this disease. In our series of 50 patients undergoing stenting for IIH, 22 for example, there were no neurological complications and no significant complications beyond the 1 case of retroperitoneal hematoma and 1 case of ruptured ovarian cyst that were reported in the initial 13 patients. Of the 4 cases in the literature with in-stent thrombosis reported, 2 were in the original study of Higgins et al 27 in which pretreatment with dual-platelet therapy was not given. The 2 subsequent cases were reported by Asif et al 28 while the patients were on 75 mg of aspirin, but were treated successfully with intravenous unfractionated heparin in 1 case and stent revision in the other. Although the case of malignant hypertension resulting in death might have resulted from cortical vein obstruction, and whereas blockage of the vein of Labbe has been demonstrated to occur in up to 92.1% of patients by Levitt et al, 29 no immediate effect on venous flow was shown. The second mortality was actually in a patient whose intracranial hypertension was not necessarily idiopathic, as there was a meningioma compressing the transverse sinus. Nevertheless, such a complication could occur in a true IIH patient as well, and this case serves as a warning that utmost care must be made to not disturbing the cortical veins during stenting. Looking at complications with alternative surgical procedures helps put stent-induced complications into context. For example, the rate of delayed intracerebral hematoma or intraventricular hemorrhage after ventriculoperitoneal shunt (VPS) placement was documented to be 4% by routine neuroradiological followup in several studies. 30, 31 In the meta-analysis of Satti et al, 23 7.6% of patients undergoing shunt for IIH experienced a major complication defined as shunt infection, tonsillar herniation, subdural hematoma, or CSF fistula, as compared with a 2.9% major complication rate of stenting (defined as the 4 cases of subdural hematoma), although they were not aware of the first death that had been reported with stenting by the time of their writing. One of the authors of this review (MD) personally observed shunt infection with secondary cortical veins and VST complicating IIH, along with a homonymous hemianopsia from repeated attempts at a posteriorly placed VPS. As for mortality after VPS, a large series reported a hospital mortality rate of 0.3% to 0.8% after VPS placement in the pediatric population with hydrocephalus, 31 which is comparable to the 0.39% mortality rate of stenting, although the study population was not specifically IIH patients, in which the mortality rate would likely be much lower than that in their population. It may be pointed out that the mortality rate in stenting may be artificially lowered owing to reluctance of some practitioners to report such a complication. This is certainly true but also likely plays a role in lowering the measured mortality rate of shunt procedures as well. Satti et al 23 found a major complication rate of 1.5% in 712 patients in the literature undergoing ONSF for IIH, which included strabismus (with 43% experiencing diplopia), retrobulbar hemorrhage, orbital hematoma, orbital apex syndrome, orbital cellulitis, and traumatic optic neuropathy.
Against
Venous stenting has been associated with an array of potential adverse effects in the literature. Of 538 patients reviewed in the literature, the most common adverse effect seems to be a headache ipsilateral to the stent, which is likely a result of dural stretching. 16 Patients need to be made aware of this adverse effect, which was reported in 104 (19.3%) patients and can last up to a week, as they might suspect worsening of their underlying disease. We found that this symptom can be relieved with a short course of corticosteroids, whereas others have treated it successfully with non-steroidal anti-inflammatory drugs.
20
Complications of the angiogram, including retroperitoneal hematoma (0.37%) 8, 32 and femoral pseudoaneurysm (0.93%), [33] [34] [35] do occur. Sequelae of antiplatelet therapy (typically dual) including melena, menorrhagia, and epistaxis (0.19% risk of each) must be monitored. 35 Allergic reactions to the contrast have also been reported (0.37%), including 1 case (0.19%) of reversible anaphylaxis.
14 Finally, life-threatening complications related directly to the stenting need to be reviewed. Thrombosis within the stent was reported in 4 patients (0.74%), with 2 of whom reported during the immediate postoperative period. 27, 28 Adjacent thrombosis occurred in another patient 36 (0.19%) and subdural or intracranial hematoma in 5 patients (0.93%).
14,21,36 Two deaths (0.37%) have been reported in the literature. The first was related to malignant intracranial hypertension, which was attributed to hypoventilation in the setting of anesthesia but raises the question of cortical vein obstruction by the stent, 37 whereas the second resulted from a cerebellar hematoma that likely resulted from a cortical vein perforation by the guidewire. 38 To conclude, it remains clear that the complications of venous stenting, although rare and comparable to those of shunt placement, can be severe and lead to death. A careful review of adverse effects and complications should be discussed with all patients undergoing stenting, and whenever possible, stenting should be performed under the auspices of a clinical trial to ensure that all complications (and all results in general) are captured. 
For
The failure rates of venous stenting in IIH patients are lower than those undergoing shunt placement (43% of patients required at least 1 additional surgery, with a mean number of 2.78 additional procedures for each failure 23 ) and also those undergoing ONSF (14.9% 23 and 31.4% 39 ). Furthermore, in our experience, the occurrence of stent-adjacent stenosis has dramatically decreased because we use a technique covering a greater portion of the transverse and sigmoid sinuses (either using 2 stents up front or a longer 70-mm stent versus the typical 30 to 40 mm).
Against
In our review, 16 treatment failure requiring repeated angioplasty or placement of a second stent occurred in 50 patients (9.3%), with recurrent stenosis being reported as the cause of failure in 35 patients (5.52%), in which 8 had recurrent in-stent stenosis and 27 developed stent-adjacent stenosis. Satti et al 23 found a similar rate of repeated procedure of 10.3% (14/136) after stenting. Kumpe et al 40 found that a purely extrinsic compression of the transverse-sigmoid sinus junction was a risk factor for stent-adjacent stenosis, presumably because extrinsic stenosis seems to result from the elevated ICP (even while it also feeds back exacerbating ICP) and is thus prone to occur again in a second location.
Statement 8: Venous Stenting Should be Considered a Viable Option in Treating IIH.
For
Since the first demonstrations of transverse sinus-sigmoid sinus stenting in 2000, the field has come a long way. 41 After 17 42 We look forward to the eventual results of planned comparative trials assessing stenting, including the VISION trial 43 and OPEN-UP trial.
44
Against
Despite a handful of small prospective studies, the bulk of data regarding VSS for patients with IIH come from either retrospective studies or case reports. Although improvements in symptoms, visual parameters, papilledema, and ICP have been demonstrated by these studies, it is difficult to attribute all of these improvements to the procedure, as patients were often still taking ICP-lowering medications and may have experienced weight loss. Carefully planned, physician-blinded, prospective, controlled studies (either against a sham stent placebo or against an alternative therapy) are needed to better understand the role of stenting in IIH. 
For
When IIH is accompanied by high-grade papilledema and severe progressive visual field loss (often with significant visual acuity loss), surgical treatments are warranted to expedite a fast reduction in ICP and resolution of papilledema to reduce the chances of permanent optic atrophy and visual loss. Recent reports of significant and immediate ICP reduction concurrent with stent placement provide reassurance that this procedure results in fast reduction of ICP.
18 Furthermore, Elder et al 45 showed significant recovery in visual fields in 2 of their 4 patients who were stented for fulminant vision loss (although 1 worsened), whereas Ahmed et al 14 also showed an improvement in vision in 4 patients with severe vision loss (although a prior ONSF in all 4 patients confounds these results). Dinkin and Patsalides 8 demonstrated an improvement in visual fields in 3 patients (6 eyes) who presented with severe papilledema and visual field loss.
Against
In cases of fulminant vision loss however, if venous stenting is not effective in reducing papilledema, options for alternative surgical therapies after stenting are limited, as dual-platelet therapy is required for 1 month after stenting and most surgeons would not want to perform either a VPS or ONSF in that setting. In such cases, one would need to wait until at least clopidogrel could be stopped before offering these alternative therapies, during which time further vision loss could ensue. Thus, when there is severe and progressive vision loss from papilledema and IIH, venous stenting should be performed with caution. 
NEURO-OPHTHALMIC COMPLICATIONS OF DURAL ARTERIOVENOUS FISTULAS
For
Depending on their location, dAVF rarely lead to visual field defects including homonymous hemianopsia. In a review of 91 patients with dAVF, hemianopsia was present in 5 (5.5%) only (Fig. 2) . 46 
Against
Homonymous visual field loss is common in the setting of cerebral arteriovenous malformations near the postgeniculate pathway, which was present in 41/171 (24%) undergoing stereotactic radiosurgery in a series, with a further 9 patients (5%) developing a new visual field defect after treatment. 47 However, dAVF are abnormal connections between one or more arteries and a dural sinus, without the mass-like tangle of vessels present in a typical arteriovenous malformation, and therefore, homonymous hemifield loss from mass effect from dAVFs is rare.
Statement 2: Dural Arteriovenous Fistulas can Mimic IIH.
For
Because dAVF can lead to arterialization of venous sinuses, elevated venous pressure can occur, leading to elevated ICP as well, thus potentially mimicking IIH. 48 Obrador et al 46 found 24/76 patients (32%) with dAVF from the literature presented with headaches, papilledema and visual loss, 13 of whom also had an audible bruit on examination. Of the 24 patients however, 11 had additional symptoms at presentation including confusion, hemiparesis, and seizures that pointed away from IIH, and one had associated subarachnoid hemorrhage. Gelwan et al 49 presented 2 cases of dAVF that presented with visual obscurations and papilledema. In both cases, suspicion for a dAVF was prompted by a longstanding complaint of unilateral pulsatile tinnitus, and an audible retroauricular bruit was discovered on examination. Searching for this bruit is a key point as IIH itself may be complicated by unilateral pulsatile tinnitus due to VSS only, but in such cases a bruit should not be present. Cognard et al 50 reported 9 cases of dAVF who presented with signs and symptoms of IIH, although CSF pressure and detailed neuro-ophthalmic examinations were not reported. In 4 of these patients, there was also a VST. It is not clear how these patients who clinically appeared to have either IIH or VST with increased ICP were designated for conventional angiograms or whether the fistulas were apparent on initial magnetic resonance imaging, magnetic resonance angiography, or MRV.
CAVERNOUS SINUS THROMBOSIS
Cavernous sinus thromboses are thrombophlebitic events in the cavernous sinus with important neuro-ophthalmic manifestations and a high mortality rate. The cavernous sinuses have extensive vascular connections that lack valves, thus allowing for blood flow in either direction. This predisposes the cavernous sinus to spread of contiguous infection, resulting in secondary thrombosis. Clinical presentation of CST includes orbital signs such as proptosis, chemosis, pupil abnormalities, ptosis, and ophthalmoplegia. 51 These clinical signs are secondary either to venous congestion within the orbit or involvement of the multiple cranial nerves (cranial nerves III, IV, V1, and V2) that line the lateral walls of the cavernous sinus, along with the more medial VIth nerve and sympathetic plexus that are adjacent to the carotid artery. 52, 53 Statement 1: Cavernous Sinus Thrombosis Should be Treated with Antibiotics.
For
Based on the underlying etiology, CST may be divided into 2 categories: septic or aseptic. Septic CST is more commonly FIGURE 2. A 64-year-old woman was referred to neuro-ophthalmology for presumed migraine aura, after she developed episodes of colorful geometric shapes in her right superior visual field. A left occipital lesion was suspected and she was sent for magnetic resonance imaging (MRI). A, Time-of-flight magnetic resonance angiogram reveals multiple vessels in the left occipital cortex suggestive of a malformation. B, Axial fluid-attenuated inversion recovery MRI reveals surrounding T2 hyperintensity, whereas axial T1 postcontrast images (C) demonstrate enhancement and a conglomeration of signal voids consistent with abnormal vessels within the parenchyma. D, A conventional cerebral angiogram of the left common carotid artery confirms left tentorial dural arteriovenous fistulas (dAVF) arising from branches of the left middle meningeal artery (MMA), posterior meningeal, and superior cerebellar arteries, with retrograde venous drainage into left occipital cortical veins (blue arrow) that ultimately drain into the superior sagittal sinus. Selective catheterization of the MMA (E) demonstrates the fistula. Onyx glue is placed within the fistula (F) with curative result. A right superior partial quadrantanopia (G) completely resolves (H) after embolization of the dAVF. 54 Septic CST is secondary to either infectious spread from contiguous structures, most frequently from the sinuses or facial soft tissue, or from hematogenous spread. 55, 56 In such case, toxins and coagulative substances are released by bacteria, promoting thrombosis. 57 Septic CST can occur in young, otherwise healthy patients. The most commonly identified bacterial pathogen is Staphylococcus aureus (60%-70% of cases); other less-commonly elicited bacteria include Streptococcus species, gram-negative bacilli, and anaerobes. Fungal pathogens have also been identified, with the most common one being Aspergillus.
Before the introduction of antibiotic therapy for these patients in the 1940s, the prognosis for patients with CST was poor. A review of 878 cases in the literature from 1821 to 1960 noted a mortality rate of 80% and morbidity of 75%. 58 Despite the introduction of antibiotics, septic CST still has a mortality rate of 20% to 30% and up to 22% of patients who recover have long-term manifestations. 53, 55 Currently, most patients are treated with broadspectrum intravenous antibiotics; the choice of which depends on the underlying organisms. Most commonly used antibiotics for CST include vancomycin or another anti-staphylococcal therapy, third-generation cephalosporins, and metronidazole. 54, 55 The proposed duration of antibiotic therapy varies in the literature but it is generally recommended that antibiotic therapy be continued for an extended period of time after resolution of symptoms, as bacteria can remain sequestered in the thrombus. 54, 59 For these patients, early diagnosis and initiation of antibiotic therapy are keys to good outcomes.
Against
Although septic CST is much more common, aseptic CST rarely occurs. They may be seen in patients with hypercoagulable states, such as neoplastic conditions. 57 Case reports of aseptic CST described patients with systemic conditions such as systemic lupus erythematous, oral contraceptive use, and thrombophilia, which predispose to thrombosis formation. 57, 60 Aseptic CST can also occur after trauma or due to mechanical factors such as compression of the venous system by intracranial tumors or masses. 56, 61 Therefore, in certain instances where a noninfectious etiology has been clearly identified, antibiotic use may be avoided.
Statement 2: There is a Role for Anticoagulation in Septic Cavernous Sinus Thrombosis.
For
In patients with aseptic CST, treatment consists of anticoagulation using heparin therapy with the goal of avoiding thrombus extension. 55, 61 In septic CST, on the other hand, the role of anticoagulation is controversial. Because of the rare nature of CST, the literature lacks large prospective studies investigating the efficacy of anticoagulation therapy. Rather, there are only a handful of retrospective papers and literature reviews. Southwick et al 62 found a mortality rate of 14% in 86 patients treated with heparin versus 36% in those who did not receive anticoagulation therapy; this demonstrated that earlier treatment was more effective. In the study of Levine et al, 63 those patients treated with anticoagulation had decreased morbidity and were noted to have more favorable neurological outcomes.
Against
There is limited evidence that adding anticoagulation to the treatment of septic CST improves outcomes. Levine et al 63 found a mortality rate of 24% in patients treated with antibiotics and anticoagulation versus 13% in patients treated with antibiotic alone. The mainstay of treatment for septic CST, therefore, remains to be antibiotic therapy with the addition of anticoagulation at the discretion of the physician. The use of anticoagulation therapy is associated with risks, with the most concern being the risk of intracranial hemorrhage. Southwick et al 62 describes 2 patients with such complications. The first was a patient who was treated with dicumarol and developed a large intracerebral hemorrhage that resulted in brainstem herniation and death. The second patient was treated with heparin and developed a subarachnoid hemorrhage, which resulted in a coma; this patient had anticoagulation reversed with vitamin K and made a full recovery. These cases highlight the importance of careful patient selection and close monitoring in patients with septic CST who are treated with anticoagulation.
VENOUS SINUS THROMBOSIS
Here we address the neuro-ophthalmic complications of sinus thrombosis outside of the cavernous sinus, which is referred as VST. This condition is of great importance to the neuroophthalmologist, as a certain percentage of patients may present with an isolated syndrome of elevated ICP due to blocked drainage of CSF into the sinus, mimicking IIH.
3 Presenting symptoms such as positional headache, pulsatile tinnitus, diplopia, and visual field loss may occur in the setting of abducens palsies and papilledema (Fig. 3) . A high clinical suspicion should be maintained in patients with systemic conditions predisposing to venous thrombotic events or who use an estrogen-containing oral contraception. Computed tomographic venography is useful as a quick and highly accurate means of diagnosing VST, but MRV, although more time consuming, is useful to monitor for progression or resolution of the thrombosis and avoids recurrent radiation exposure to patients, of whom many are young women of childbearing age. Standard-of-care treatment of VST is anticoagulation, but for refractory cases, there is now evidence from several studies that endovascular mechanical thrombectomy can be effective. 
For
Acetazolamide is a carbonic anhydrase inhibitor that decreases CSF production and has been used for decades as a first-line treatment for IIH. 65 The IIH Treatment Trial provided evidence to support this practice, demonstrating that its use alongside a weight-loss program resulted in a greater improvement in visual fields than weight loss alone in patients with mild IIH. 66 Patients treated with acetazolamide were also noted to have significant improvement in retinal nerve fiber layer thicknesses on optical coherence tomography, 67 in Frisén papilledema grade, 68 and opening pressure.
68
Literature supporting the use of acetazolamide for papilledema secondary to cerebral venous thromboses is limited, but we have seen cases where patients were treated only with anticoagulation, with the assumption that resolution of the VST would in turn lead to resolution of the papilledema, but resulting in significant visual field loss. Such an outcome is a result of the fact that, although anticoagulation prevents the propagation of thrombus, it may still take weeks for the thrombotic region to recanalize. In the meantime, ICP remains high, and papilledema may remain untreated, with consequent permanent damage to the optic disc. It has, therefore, been proposed that acetazolamide should be used in patients with cerebral venous thrombosis to treat papilledema and to treat and prevent vision loss. 3, 69 Despite the recommendations of the European Stroke Organisation (ESO), we recommend acetazolamide for any cases of VST where there is papilledema or clear evidence of elevated ICP.
Against
Despite its proven benefits in the treatment of papilledema, acetazolamide therapy is not without risks. Common sideeffects of acetazolamide include paresthesias, dysgeusia, gastrointestinal issues, and frequent urination. Metabolic acidosis and hypokalemia are more serious potential complications that can result from acetazolamide use. In the IIH Treatment Trial, the rate of these side-effects was significantly greater with acetazolamide treatment compared with the placebo group, and there were 3 times more serious adverse events in the acetazolamide group compared with the control group. 9 Furthermore, there is a theoretical risk that dehydration due to acetazolamide could exacerbate the VST. Given these risks and the lack of randomized controlled clinical trials investigating the efficacy of acetazolamide in patients with cerebral venous thrombosis, the ESO recommendation is that there is not enough evidence for the use of acetazolamide in these patients. However, their recommendations do note that acetazolamide can be used in patients with vision-threatening papilledema who are at low risk for complications from acetazolamide therapy. A CCF is an aberrant connection between the arteries and veins within the cavernous sinus. It is divided into 2 types: direct 71 Direct CCF is a high-flow fistula and involves a direct connection between the cavernous sinus and the internal carotid artery. It is often the sequela of a traumatic insult, aneurysmal rupture, or secondary to surgical complications. Dural CCF, on the other hand, is commonly a low-flow fistula that results from communication between the cavernous arterial branches and the cavernous sinus 72 and is most common in middle-aged women. It is hypothesized that the pathogenesis of dural CCF involves thrombosis of the cavernous sinus resulting in anastomosis between the arterial and venous system as collateral outflow for the cavernous sinus.
72,73
Typically, CCF presents with neuro-ophthalmic symptoms including chemosis, proptosis, corkscrew scleral vessels, elevated intraocular pressure, and dysfunction of intra-cavernous cranial nerves including III, IV, and VI. The abducens nerve is most commonly affected due to its proximity to the carotid artery. An orbital bruit may be heard by the patient or physician if the eye is auscultated with a stethoscope. Fluctuating symptoms can mimic ocular myasthenia. 74 Direct CCF typically presents more acutely and with more severe symptoms than indirect CCF. Although direct CCF most often needs to be treated, the management of indirect CCF is more nuanced.
For
A number of surgical treatment options exist for patients with dural CCF but the surgical intervention of choice is endovascular embolization. Embolization can be performed with a number of different organic or inorganic materials. Another treatment option is transvenous coiling. Indications for surgery include progressive symptoms or the presence of cortical venous reflux, which predicts risk of hemorrhage. 75 Rates of successful closure with surgical intervention are high, up to 70% to 100%. Complications from intervention include, but are not limited to, hemorrhage, infection, and neurological deficits. However, these complications are rare. Another argument for performing surgical intervention is that despite the low risk in these patients, FIGURE 4 . A 64-year-old woman presented with mild vertical diplopia and headache and was found to have an indirect carotid-cavernous fistula within the right cavernous sinus. A, Magnetic resonance angiogram of the head reveals arterial flow within the right cavernous sinus suggestive of a cavernouscarotid fistula (arrow). B, Conventional cerebral angiogram confirms an indirect fistula with arterial feeders arising from meningeal branches of the meningohypophyseal trunk and right middle meningeal arteries (arrowheads), with drainage into the inferior petrosal sinuses (arrow) and into the cavernous sinus. Because her examination revealed a comitant right hypertropia inconsistent with a trochlear palsy, the fistula was felt to be incidental and observation was recommended. However, she decided to pursue embolization to prevent future complications. After the procedure, she developed severe horizontal diplopia and was found to have a complete right abducens palsy, presumably due to ischemia caused by mass effect from the coils placed in the cavernous sinus during the embolization. C, T1 postaxial magnetic resonance imaging (MRI) of the brain demonstrates hypoenhancing signal consistent with postembolization material (arrow). D, T2 coronal MRI of the brain demonstrates atrophy of the lateral rectus muscle and T2 hyperintensity consistent with lateral rectus denervation (arrow). As this diplopia was not amenable to prismatic therapy, she eventually went for strabismus repair. progression to a high-flow CCF can occur and can ultimately result in ocular manifestations that can have a long-term impact on visual outcomes.
73,75,76
Against
Although direct CCF may result in dangerously elevated ICP and severe cranial neuropathies, and should be treated with embolization in the majority of cases, the data are not clear for dural fistulas in which symptoms are milder and in which there may be spontaneous resolution. Patients with these indirect CCF have no difference in mortality rate compared with the general population and often present with only ocular symptoms such as increased intraocular pressure and proptosis. The spontaneous resolution of dural CCF occurs in 20% to 50% of patients, often after angiography, and the rate of serious complications such as spontaneous hemorrhage is low. 73, 75 Because these lesions do not confer increased mortality, many experts recommend close observation and symptomatic management. 74, 77 Intraocular pressure, visual function, proptosis, and optic nerve appearance should be monitored closely in these patients as progression of symptoms is an indication for surgical intervention. Furthermore, embolization is not without possible complications (Fig. 4) .
CONCLUSIONS
Dysfunction of the cerebral venous sinuses often manifests as visual dysfunction, due to unique anatomical factors that link the 2 together. Papilledema may be the first manifestation of VST or dAVF, along with IIH, which is associated with VSS at the transverse sinus-sigmoid sinus junction. Similarly, diplopia may herald thrombosis, tumor, fistulas, or inflammation of the cavernous sinus, as all 3 cranial nerves that govern ocular motility traverse its trabeculae. Practicing ophthalmologists should be familiar with these conditions, as the associated visual symptoms and signs may bring afflicted patients to them first. Prompt and accurate diagnosis of these conditions can help prevent longlasting visual dysfunction from ensuing, and in some cases, reduce mortality.
